Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study

Table 3 Dynamic changes in liver function and coagulation parameters in the recombinant human thrombopoietin and control groups

Variables	rhTPO (n = 35)	Control (n = 35)	P value1
Alanine transaminase, U/L
Baseline	34.0 (20.0, 71.0)	64.0 (35.0, 148.0)	0.003
Day 7	27.0 (18.0, 36.0)a	46.0 (22.0, 72.5)a	0.009
Day 7 change from baseline	-8 (-22, -3)	-18 (-50.5, -6.5)	0.050
Day 14	26.0 (15.0, 41.0)a	35.0 (18.0, 53.0)a	0.346
Day 14 change from baseline	-9 (-33, 3)	-19.5 (-61, -8)	0.063
Aspartate transaminase, U/L
Baseline	59.0 (36.0, 106.0)	82.0 (45.0, 173.0)	0.152
Day 7	42.0 (30.0, 71.0)a	57.0 (31.0, 97.0)a	0.209
Day 7 change from baseline	-17 (-36, -2)	-20 (-141, 0)	0.398
Day 14	49.0 (27.0, 71.0)a	46.0 (27.0, 56.0)a	0.678
Day 14 change from baseline	-21.5 (-34, 3)	-46 (-106, -15)	0.056
Albumin, g/L
Baseline	28.2 (24.4, 31.7)	27.5 (22.8, 31.8)	0.742
Day 7	29.6 (26.0, 32.1)a	29.8 (26.5, 32.0)a	1.000
Day 7 change from baseline	1.7 (-1.0, 4.2)	2.9 (-2.0, 6.7)	0.611
Day 14	32.6 (29.3, 35.3)a	31.7 (26.3, 33.8)a	0.318
Day 14 change from baseline	4.9 (0.8, 8.6)	4.0 (0.0, 6.6)	0.323
Total bilirubin, μmol/L
Baseline	88.8 (76.3, 144.1)	113.9 (95.2, 132.7)	0.053
Day 7	91.8 (51.5, 138.9)a	105.3 (84.3, 119.8)	0.143
Day 7 change from baseline	-12.5 (-41.8, 6.7)	-10.5 (-31.1, 9.7)	0.787
Day 14	82.4 (49.9, 154.7)	86.2 (61.1, 121.1)a	0.920
Day 14 change from baseline	-29.0 (-43.1, 9.0)	-25.6 (-51.6, -4.9)	0.681
MELD
Baseline	17 (9.0, 22)	18 (13.8, 23)	0.187
Day 7	15 (8.5, 18.5)	16 (13, 19)	0.230
Day 7 change from baseline	-1 (-3, 1)	-1 (-5, 1)	0.791
Day 14	15 (10.5, 16.5)a	15 (11, 21)	0.087
Day 14 change from baseline	-2 (-6.5, 0)	-2 (-5, 1)	0.676
INR
Baseline	1.7 (1.5, 2.1)	2.1 (2.0, 2.6)	0.088
Day 7	1.7 (1.5, 2.0)a	2.0 (1.7, 2.2)a	0.017
Day 7 change from baseline	-0.085 (-0.330, 0.030)	-0.140 (-0.575, 0.055)	0.493
Day 14	1.5 (1.4, 1.8)a	2.0 (1.8, 2.3)	< 0.001
Day 14 change from baseline	-0.22 (-0.34, -0.08)	-0.105 (-0.450, 0.035)	0.293

^aP < 0.05 indicates statistically significant differences comparing with baseline.

¹P value indicates the comparison of variables between recombinant human thrombopoietin group and control group.

Values are expressed as median (Q1-Q3). rhTPO: Recombinant human thrombopoietin; MELD: Model for end-stage liver disease; INR: International normalized ratio.